| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
The primary molecular targets of Hymenidin are serotonergic receptors and voltage-gated potassium channels. It acts as an antagonist at 5-hydroxytryptaminergic receptors, blocking serotonin-mediated signaling. Hymenidin also inhibits voltage-gated potassium channels, modulating membrane excitability. Additionally, it selectively binds to FOXO1 DNA, a transcription factor involved in apoptosis and cell cycle regulation.
|
|---|---|
| ln Vitro |
In vitro, Hymenidin is a natural antagonist of serotonergic receptors and an inhibitor of voltage-gated potassium channels. It reduces depolarization-induced elevation of cellular calcium. Hymenidin induces apoptosis in cancer cells. It selectively binds to FOXO1 DNA. Specific IC50 values for receptor antagonism and potassium channel inhibition have not been extensively reported.
|
| ln Vivo |
No dedicated in vivo efficacy studies have been published specifically for Hymenidin. As a natural marine alkaloid, its in vivo applications are primarily in preclinical models of cancer and parasitic infections. No pharmacokinetic parameters, maximum tolerated doses, or in vivo efficacy data are available in the published literature.
|
| Enzyme Assay |
Non-cell-based assays for Hymenidin use radioligand binding with [3H]serotonin or [125I]iodocyanopindolol in membrane preparations from cells expressing serotonergic receptors. Membranes are incubated with radioligand and increasing concentrations of Hymenidin in assay buffer. Bound radioligand is separated by rapid filtration, and radioactivity is quantified.
|
| Cell Assay |
Cell-based assays for Hymenidin use cancer cell lines or cells expressing voltage-gated potassium channels. Cells are cultured in standard medium and treated with Hymenidin at concentrations ranging from 0.1 to 100 μM. Cell viability is measured by MTT assay. Apoptosis is assessed by Annexin V/PI staining and caspase activity assays. Potassium currents are measured by patch-clamp electrophysiology.
|
| Animal Protocol |
No specific in vivo animal protocols have been established for Hymenidin. For potential evaluation, the compound could be administered in murine tumor xenograft models or parasite infection models. Doses would be determined from pharmacokinetic studies. Endpoints could include tumor growth inhibition or parasite burden.
|
| References |
|
| Additional Infomation |
Hymenidin has reportedly been found in Stylissa carteri, Agelas nakamurai, and other organisms with available data.
|
| Molecular Formula |
C11H12N5OBR
|
|---|---|
| Molecular Weight |
310.14988
|
| Exact Mass |
309.023
|
| CAS # |
107019-95-4
|
| Related CAS # |
107019-95-4 Hymenidin
|
| PubChem CID |
6439099
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.69g/cm3
|
| Index of Refraction |
1.742
|
| Source |
Marine naturally occuring products: Sponge
|
| LogP |
2.497
|
| tPSA |
99.59
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
18
|
| Complexity |
325
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
NC1=NC=C(/C=C/CNC(C2=CC(Br)=CN2)=O)N1
|
| InChi Key |
KHJREOQCERRAME-OWOJBTEDSA-N
|
| InChi Code |
InChI=1S/C11H12BrN5O/c12-7-4-9(15-5-7)10(18)14-3-1-2-8-6-16-11(13)17-8/h1-2,4-6,15H,3H2,(H,14,18)(H3,13,16,17)/b2-1+
|
| Chemical Name |
N-[(E)-3-(2-amino-1H-imidazol-5-yl)prop-2-enyl]-4-bromo-1H-pyrrole-2-carboxamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2242 mL | 16.1212 mL | 32.2425 mL | |
| 5 mM | 0.6448 mL | 3.2242 mL | 6.4485 mL | |
| 10 mM | 0.3224 mL | 1.6121 mL | 3.2242 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
